Abstract
The presence of mixed dyslipidemia and moderately high liver function tests is usually correctly assessed as the presence of liver steatosis; however, the approach to the prevention of atherosclerotic cardiovascular disease (aKVO) will not fundamentally alter this finding. However, the presence of steatosis or higher stages of hepatic impairment is not only a risk factor for cirrhosis and liver failure, but above all for ACL.
Given the growing knowledge, possible approaches to these findings will change and the presence of hepatic steatosis will be considered as another significant risk factor for aVOE. This would mean paying attention to improving the overall condition of liver cells in addition to the already established pathways that also pass through these cells, ie, the multiplication and recycling of LDL receptors.
Reducing simple carbohydrates, especially fructose, and reducing visceral fat with sufficient physical activity are obviously crucial to achieving this goal; in extreme cases, bariatric surgery is good. The possibilities of pharmacological therapy are being studied intensively.
Promising drugs include hypolipemics, antidiabetics, and some hepatoprotectives. Given this, and from the perspective of a hepatologist focused on liver problems, the presence of steatosis or other stages of hepatic impairment should also arouse interest in the lipid spectrum and other risk factors for ACL.